Decoy Therapeutics Inc. (DCOY) shareholders
Close on Nov 17, 2026Market cap $622.03KP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| CVI Investments, Inc. Joint filing with Heights Capital Management, Inc. (9.90%) | 708,565 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Heights Capital Management, Inc. Joint filing with CVI Investments, Inc. (9.90%) | 362,499 | 9.90% | 13G (passive) | Nov 11, 2025 |
| Steven Boyd Joint filing with Armistice Capital, LLC (9.99%) | 65,503 | 9.99% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DCOY | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 4,034 | 0.62% | $29.00K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 256 | 0.04% | $1.84K | −765 | 0.00% |
| UBS Group AG | 25 | 0.00% | $180 | −521 | 0.00% |
| Caitong International Asset Management Co., Ltd | 2 | 0.00% | $14 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 4 | 0M | 0.7% | 2 / 0 | 2 / 2 | 0M | 0M |
| Q1 2026 | 4 | 0M | 0.2% | 4 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of DCOY | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 5,156 | 0.79% | $45.89K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 4,034 | 0.62% | $29.00K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 477 | 0.07% | $4.25K | 0.00% | May 31, 2026 |
| Horizon Kinetics Medical ETF | 21 | 0.00% | $149 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Frederick Pierce Ii | Chief Executive Officer | 34,844 | 5.32% | Sep 2, 2026 |
| Mark J. Rosenblum | Chief Financial Officer | 11,363 | 1.73% | Sep 2, 2026 |
| Peter Klaus Marschel | Chief Business Officer | 3,900 | 0.60% | Sep 2, 2026 |
| Barbara Louise Hibner | Chief Scientific Officer | 4,216 | 0.64% | Sep 2, 2026 |
| William K. McVicar | Director | 4,064 | 0.62% | Sep 2, 2026 |
| Patricia G. Gauthier | Director | 2,000 | 0.31% | Sep 2, 2026 |
| Jonathan I. Lieber | Director | 2,002 | 0.31% | Sep 2, 2026 |
| Arnold C. Hanish | Director | 8,418 | 1.28% | Sep 2, 2026 |
| Tess Burleson | Director | 2,002 | 0.31% | Sep 2, 2026 |
| Paul Lammers | Director | 2,001 | 0.31% | Sep 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jonathan I. Lieber Director | Aug 31, 2026 | Award | +2,000 | – | – | 2,002 |
| William K. McVicar Director | Aug 31, 2026 | Award | +3,000 | – | – | 3,002 |
| Arnold C. Hanish Director | Aug 31, 2026 | Award | +3,000 | – | – | 3,418 |
| Paul Lammers Director | Aug 31, 2026 | Award | +2,000 | – | – | 2,001 |
| Frederick Pierce Ii Chief Executive Officer | Aug 31, 2026 | Award | +33,455 | – | – | 34,844 |
| Patricia G. Gauthier Director | Aug 31, 2026 | Award | +2,000 | – | – | 2,000 |
| Barbara Louise Hibner Chief Scientific Officer | Aug 31, 2026 | Award | +4,216 | – | – | 4,216 |
| Peter Klaus Marschel Chief Business Officer | Aug 31, 2026 | Award | +3,900 | – | – | 3,900 |
| Tess Burleson Director | Aug 31, 2026 | Award | +2,000 | – | – | 2,002 |
| Mark J. Rosenblum Chief Financial Officer | Aug 31, 2026 | Award | +9,682 | – | – | 11,363 |
| Arnold C. Hanish Director | Dec 30, 2025 | Sale | −12 | $0.64 | $8 | 0 |
| Arnold C. Hanish Director | Dec 30, 2025 | Sale | −15 | $0.64 | $10 | 5,000 |
| Arnold C. Hanish Director | Nov 20, 2025 | Buy | +5,000 | $0.75 | $3.75K | 5,015 |
| Mark J. Rosenblum Exec VP Finance, CFO | Nov 20, 2025 | Buy | +20,000 | $0.80 | $16.00K | 20,177 |
| Mark J. Rosenblum Exec VP Finance, CFO | Feb 13, 2023 | Award | +6,432 | – | – | 21,851 |
| David J. Arthur Chief Executive Officer, Director | Feb 13, 2023 | Award | +14,300 | – | – | 48,019 |
| William K. McVicar Director | Jan 3, 2023 | Award | +1,440 | – | – | 1,788 |
| Jonathan I. Lieber Director | Jan 3, 2023 | Award | +1,440 | – | – | 2,940 |
| David J. Arthur Chief Executive Officer, Director | Jan 3, 2023 | Award | +20,000 | – | – | 33,719 |
| Paul Lammers Director | Jan 3, 2023 | Award | +1,440 | – | – | 1,718 |
| Tess Burleson Director | Jan 3, 2023 | Award | +1,440 | – | – | 2,722 |
| Mark J. Rosenblum Exec VP Finance, CFO | Jan 3, 2023 | Award | +8,000 | – | – | 15,419 |
| Bruce J. McCreedy Jr. Director | Jan 3, 2023 | Award | +1,440 | – | – | 1,788 |
| Arnold C. Hanish Director | Jan 3, 2023 | Award | +1,440 | – | – | 1,440 |
| Mark J. Rosenblum Exec VP Finance, CFO | Nov 3, 2022 | Award | +1,488 | $1.73 | $2.57K | 7,419 |
| David J. Arthur Chief Executive Officer, Director | Nov 3, 2022 | Award | +2,693 | $1.73 | $4.66K | 13,719 |
| Mark J. Rosenblum Exec VP Finance, CFO | Nov 3, 2022 | Award | +7,314 | $1.73 | $12.65K | 13,245 |
| David J. Arthur Chief Executive Officer, Director | Nov 3, 2022 | Award | +10,000 | $1.73 | $17.30K | 21,026 |
| David J. Arthur Chief Executive Officer, Director | Nov 3, 2022 | Award | +10,000 | $1.73 | $17.30K | 285,674 |
| Mark J. Rosenblum Exec VP Finance, CFO | Nov 3, 2022 | Award | +7,314 | $1.73 | $12.65K | 155,633 |
| Jonathan I. Lieber Director | Jun 7, 2022 | Buy | +37,500 | $0.19 | $7.13K | 37,500 |
| Tess Burleson Director | Jun 7, 2022 | Buy | +27,700 | $0.18 | $4.99K | 32,050 |
| William K. McVicar Director | Jun 6, 2022 | Buy | +26,553 | $0.19 | $5.05K | 26,553 |
| Arnold C. Hanish Director | Jun 3, 2022 | Buy | +28,000 | $0.18 | $5.04K | 46,350 |
| Mark J. Rosenblum Exec VP Finance, CFO | May 31, 2022 | Buy | +28,000 | $0.18 | $5.04K | 148,319 |
| David J. Arthur Chief Executive Officer, Director | May 26, 2022 | Buy | +708 | $0.18 | $127 | 282,382 |
| David J. Arthur Chief Executive Officer, Director | May 26, 2022 | Buy | +18,600 | $0.18 | $3.35K | 281,674 |
| David J. Arthur Chief Executive Officer, Director | May 26, 2022 | Buy | +3,400 | $0.18 | $612 | 263,074 |
| David J. Arthur Chief Executive Officer, Director | May 26, 2022 | Buy | +10,800 | $0.18 | $1.94K | 303,574 |
| David J. Arthur Chief Executive Officer, Director | May 26, 2022 | Buy | +10,392 | $0.18 | $1.87K | 292,774 |
| Mark J. Rosenblum Exec VP Finance, CFO | May 3, 2022 | Award | +10,000 | $0.19 | $1.90K | 120,319 |
| David J. Arthur Chief Executive Officer, Director | May 3, 2022 | Award | +10,000 | $0.19 | $1.90K | 259,674 |
| David J. Arthur Chief Executive Officer, Director | Mar 3, 2022 | Buy | +139,488 | $0.39 | $54.40K | 249,674 |
| Mark J. Rosenblum Exec VP Finance, CFO | Mar 3, 2022 | Buy | +76,246 | $0.39 | $29.74K | 110,319 |
| Mark J. Rosenblum Exec VP Finance, CFO | Nov 3, 2021 | Award | +7,787 | $0.72 | $5.61K | 34,073 |
| David J. Arthur Chief Executive Officer, Director | Nov 3, 2021 | Award | +7,939 | $0.72 | $5.72K | 110,186 |
| David J. Arthur Chief Executive Officer, Director | Aug 17, 2021 | Buy | +2,000 | $0.89 | $1.78K | 102,247 |
| David J. Arthur Chief Executive Officer, Director | Aug 17, 2021 | Buy | +2,000 | $0.90 | $1.80K | 100,247 |
| Arnold C. Hanish Director | Aug 10, 2021 | Buy | +7,000 | $0.88 | $6.16K | 18,350 |
| David J. Arthur Chief Executive Officer, Director | May 3, 2021 | Award | +9,822 | $0.57 | $5.60K | 96,247 |
| Mark J. Rosenblum Exec VP Finance, CFO | May 3, 2021 | Award | +9,563 | $0.57 | $5.45K | 26,286 |
| David J. Arthur Chief Executive Officer, Director | Nov 3, 2020 | Award | +4,879 | $0.56 | $2.73K | 86,425 |
| Mark J. Rosenblum Exec VP Finance, CFO | Nov 3, 2020 | Award | +4,723 | $0.56 | $2.64K | 16,723 |
| Arnold C. Hanish Director | Aug 21, 2020 | Buy | +4,000 | $0.98 | $3.92K | 11,350 |
| Arnold C. Hanish Director | Aug 21, 2020 | Buy | +4,000 | $0.98 | $3.92K | 11,350 |
| David J. Arthur Chief Executive Officer, Director | Aug 19, 2020 | Buy | +1,000 | $1.01 | $1.01K | 2,000 |
| David J. Arthur Chief Executive Officer, Director | Aug 19, 2020 | Buy | +1,000 | $1.01 | $1.01K | 1,000 |
| Mark J. Rosenblum Exec VP Finance, CFO | Aug 17, 2020 | Buy | +5,000 | $1.00 | $5.00K | 12,000 |
| Mark J. Rosenblum Exec VP Finance, CFO | Feb 19, 2020 | Buy | +2,000 | $0.95 | $1.90K | 7,000 |
| Scott Jordan Chief Business Officer | Feb 18, 2020 | Buy | +11,300 | $0.90 | $10.17K | 31,609 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 10 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Decoy Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 764,407 shares on Sep 23, 2026 over the last 90 days.
See a number that looks wrong?